Results 121 to 130 of about 91,755 (270)

Contemporary Treatment Patterns in Surgically Treated Temporal Bone Cancer

open access: yesThe Laryngoscope, EarlyView.
In a national cohort of 811 surgically treated temporal bone cancer patients, adjuvant radiation therapy was the most frequently utilized postoperative treatment (20.3%), while chemotherapy and immunotherapy were used far less frequently. Multimodal treatment, particularly combined parotidectomy and neck dissection, was strongly associated with higher ...
Raquel Rowell   +4 more
wiley   +1 more source

Effektivität von Nivolumab mit Mutationslast assoziiert

open access: yes, 2017
Im Vergleich mit einer platinbasierten Doublet-Chemotherapie verlängert der Checkpoint-Inhibitor Nivolumab in der Zweitlinientherapie das progressionsfreie Überleben (PFS) vorbehandelter Patienten mit einem metastasierten nicht kleinzelligen ...
Susanne Krome
core   +1 more source

Organoid Coculture Models for Cancer Research and Immunotherapy

open access: yesMed Research, EarlyView.
This review summarizes organoid coculture platforms, including submerged Matrigel culture, air–liquid interface, microfluidic/organoid‐on‐a‐chip, and 3D bioprinting, for reconstructing the tumor microenvironment to study tumor–stroma/immune crosstalk, evaluate immunotherapies, and enable drug screening.
Zhuo Yang   +9 more
wiley   +1 more source

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab

open access: yes, 2017
Cancer immunotherapy by targeting of immune checkpoint molecules has been a research ‘hot-spot’ in recent years. Nivolumab, a human monoclonal antibody targeting PD-1, has been widely used clinically since 2014.
George F. Gao   +15 more
core   +1 more source

The efficacy of concurrent chemoradiotherapy with or without nimotuzumab in high‐risk patients with locally advanced head and neck squamous cell carcinoma post‐surgery: A real‐world study

open access: yesPrecision Radiation Oncology, EarlyView.
Figure 1 Patient selection flowchart. CCRT, concurrent chemoradiotherapy; NCCRT, nimotuzumab and concurrent chemoradiotherapy. Abstract Purpose Patients with locally advanced head and neck squamous cell carcinoma (LA‐HNSCC) harboring high‐risk pathological features after radical surgery face high recurrence rates.
Yuejia Zhou   +8 more
wiley   +1 more source

The role of nivolumab in melanoma

open access: yes, 2018
The incidence of melanoma continues to rise worldwide. Prior to 2010, there had been no progress in the treatment of advanced melanoma in living memory.
Serra-Bellver, P   +8 more
core   +1 more source

Dosimetric risk factors for therapy‐related pneumonitis in patients with immunotherapy plus chemotherapy concurrent thoracic radiotherapy

open access: yesPrecision Radiation Oncology, EarlyView.
In this study, mean lung dose (MLD) and age were associated with an increased risk of treatment‐related pneumonitis in patients receiving concurrent chemoradiotherapy and immunotherapy, providing a reference for revising lung dose constraints. Abstract Objective Combining immune checkpoint inhibitors (ICIs) with chemoradiotherapy is being actively ...
Ying Lu   +9 more
wiley   +1 more source

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada   +13 more
wiley   +1 more source

Diffuse Skin Sclerosis in a Patient With Lung Cancer

open access: yes
JEADV Clinical Practice, EarlyView.
Anna‐Sophia Leven   +2 more
wiley   +1 more source

4′‐Hydroxywogonin Attenuates Hepatocellular Carcinoma Progression by Suppressing Gas6/Axl‐PI3K/AKT Signaling

open access: yesPhytotherapy Research, EarlyView.
4′‐Hydroxywogonin, a flavonoid derived from Scutellaria baicalensis, inhibits hepatocellular carcinoma progression partly by suppressing Gas6/Axl‐PI3K/AKT signaling, inducing cell cycle arrest and apoptosis, and reducing metastatic potential. It also suppresses xenograft tumor growth without evident hepatotoxicity.
Chi‐Yuan Chen   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy